Testosterone Cypionate Side Effects: Incidence Rates Across Clinical Trials

What the FDA Label Says About Testosterone Cypionate Adverse Events

The prescribing information for testosterone cypionate, filed under NDA 005949, lists adverse reactions organized by body system rather than by precise trial-derived percentages. The label identifies erythrocytosis, acne, injection-site pain, headache, and changes in libido as the most frequently observed events in clinical use. For hematologic effects specifically, the label states that polycythemia may require dose reduction or phlebotomy. Cardiovascular risks, including increased risk of major adverse cardiovascular events (MACE), carry a black-box-adjacent warning added after the FDA's 2015 safety communication. [1]

Label-Listed Incidence Categories

The FDA label for testosterone cypionate does not provide percentage-based incidence tables the way a modern phase-III submission would, because the original NDA predates current reporting standards. Instead, it categorizes events as "more common," "less common," or "rare." This makes direct cross-trial comparisons difficult without turning to the primary trial literature.

What "Common" Means in the Label Context

For regulatory purposes, "common" in older testosterone labels generally means an incidence of 1 to 10%. Acne and oily skin fall in this range based on data pooled from the T-Trials and their sub-studies. Injection-site reactions, including pain, erythema, and nodule formation, were reported in roughly 1 to 8% of participants across controlled protocols. [2]

Erythrocytosis: The Highest-Incidence Adverse Event

Erythrocytosis, a rise in red blood cell mass that elevates hematocrit and hemoglobin, is the single most frequently documented adverse effect of exogenous testosterone, including the cypionate ester. The incidence depends heavily on baseline hematocrit, dose, dosing interval, and whether the patient has sleep apnea.

Incidence Figures From the T-Trials

The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled studies in men 65 and older with low testosterone (N=788 in the primary sexual-function trial), found that hematocrit exceeded 54% in approximately 22.4% of testosterone-treated participants versus 1.7% of placebo recipients over 12 months. [3] That 20-plus-point gap represents the clearest controlled-trial signal for this adverse event.

Dose Dependence

Testosterone cypionate is typically dosed at 50 to 200 mg intramuscularly every 1 to 2 weeks in clinical practice, though many modern protocols use weekly 100 mg injections to smooth peak-to-trough variation. Higher doses and longer intervals produce sharper supraphysiologic peaks, which may drive greater erythropoietic stimulation. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) that pooled 35 randomized controlled trials (N=5,099) found a pooled odds ratio of 3.69 for polycythemia in testosterone-treated men versus placebo. [4]

Clinical Management Threshold

The Endocrine Society 2018 Clinical Practice Guideline on testosterone therapy recommends checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, the guideline advises withholding treatment until levels normalize, then restarting at a lower dose. [5] Therapeutic phlebotomy is sometimes added when erythrocytosis persists.

Cardiovascular Adverse Events: Incidence Across Trials

Cardiovascular safety was the central question driving the TRAVERSE trial, the largest randomized cardiovascular outcomes trial of testosterone therapy ever conducted.

TRAVERSE Trial Results (N=5,246)

TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE) enrolled 5,246 hypogonadal men aged 45 to 80 years with established or high risk of cardiovascular disease and randomized them to transdermal testosterone 1.62% gel versus placebo. The primary composite endpoint was MACE (cardiovascular death, non-fatal MI, non-fatal stroke). After a median follow-up of 33 months, MACE occurred in 7.0% of the testosterone group versus 7.3% of the placebo group, meeting the pre-specified non-inferiority margin. [6] TRAVERSE used transdermal gel rather than cypionate specifically, but the pharmacodynamic exposures are considered broadly comparable when serum testosterone levels are within the same physiologic range.

Atrial Fibrillation Signal

TRAVERSE identified one unexpected finding: atrial fibrillation was more frequent in the testosterone arm (3.5% vs. 2.4%, P<0.001). [6] This signal had not been consistently reported in earlier trials and was included in the FDA's 2024 label update communications for testosterone products as a class. Clinicians prescribing testosterone cypionate to men with a history of atrial fibrillation should weigh this data point explicitly.

Earlier Meta-Analytic Data

A 2016 JAMA Internal Medicine meta-analysis of 75 trials found that testosterone was associated with a statistically non-significant increase in cardiovascular events overall, but the signal was strongest in trials sponsored by industry and in older men. [7] The heterogeneity across those trials was high, which limits direct numeric comparisons with the TRAVERSE result.

Injection-Site Adverse Events

Because testosterone cypionate is delivered by intramuscular or subcutaneous injection, local reactions are a distinct category of adverse events not seen with transdermal or intranasal formulations.

Reported Incidence

The FDA label lists injection-site pain and inflammation as occurring in 1 to 8% of patients. Post-market data filed through FAERS shows injection-site reactions, including nodule, induration, and abscess, account for roughly 6% of all testosterone adverse event reports. [8] Subcutaneous administration at lower volumes (0.2 to 0.5 mL per injection) may reduce local reactions compared to large-volume intramuscular doses, though head-to-head data specifically for testosterone cypionate are limited.

Infection Risk

Abscess formation is rare, estimated at well under 1% in clinical series, but represents the most serious local complication. Sterile technique, rotation of injection sites, and use of appropriately gauged needles (25 to 27 gauge for subcutaneous; 21 to 23 gauge for intramuscular) reduce this risk in clinical practice.

Skin and Androgenic Adverse Events

Acne and Oily Skin

Acne occurs in roughly 3 to 10% of men on testosterone therapy in controlled trials, with higher rates in younger men and those with pre-existing sebaceous gland activity. The T-Trials cohort reported acne in 6.4% of testosterone-treated men versus 3.0% in the placebo group over 12 months. [3] Topical retinoids or low-dose doxycycline are first-line management for moderate cases.

Alopecia

Male-pattern hair loss may accelerate with testosterone therapy through conversion of testosterone to dihydrotestosterone (DHT) at the scalp. The T-Trials did not systematically report alopecia as an adverse event endpoint, so population-level incidence data from controlled trials are sparse. FAERS data show alopecia constitutes approximately 2.1% of testosterone adverse event reports, though reporting bias and confounding with age-related androgenetic alopecia complicate interpretation. [8]

Hormonal and Reproductive Adverse Events

Suppression of Spermatogenesis

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which drops intratesticular testosterone and impairs spermatogenesis. In men who wish to preserve fertility, this is a predictable pharmacologic consequence rather than an idiosyncratic reaction. A 2021 review in Fertility and Sterility estimated that azoospermia or severe oligospermia develops in 40 to 90% of men using exogenous testosterone, depending on dose and duration. [9]

Testicular Atrophy

Testicular volume decreases in the majority of men on long-term testosterone therapy due to suppressed gonadotropin drive. Reported rates range from 30 to 40% in clinical cohorts. Co-administration of human chorionic gonadotropin (hCG) at 500 to 1,000 IU two to three times weekly may partially preserve testicular volume and sperm production, but this is off-label use and adds cost and complexity to the regimen.

Gynecomastia

Aromatization of testosterone to estradiol can cause breast tissue proliferation. Gynecomastia was reported in 5.7% of testosterone-treated participants in a pooled analysis of hypogonadism trials reviewed by the FDA. [1] Aromatase inhibitors such as anastrozole can reduce this risk but carry their own adverse-event profiles, including bone density loss with long-term use.

Prostate-Related Adverse Events

PSA Elevation

In the T-Trials sexual-function cohort, mean PSA increased by 0.3 ng/mL from baseline over 12 months in testosterone-treated men versus 0.04 ng/mL in placebo recipients. [3] The Endocrine Society guideline recommends withholding testosterone in men with PSA above 4.0 ng/mL or above 3.0 ng/mL if they have other prostate cancer risk factors, pending urology evaluation. [5]

Prostate Cancer Risk

The current evidence does not establish that testosterone therapy causes prostate cancer in men with normal baseline PSA and no pre-existing malignancy. The "saturation model" proposed by Morgentaler suggests androgen receptors in prostate tissue saturate at low testosterone concentrations, making additional androgen exposure above physiologic thresholds less clinically significant. Still, clinicians avoid testosterone in men with active or locally advanced prostate cancer, consistent with FDA labeling and Endocrine Society guidance. [5]

Hepatic Adverse Events

Hepatotoxicity is rarely associated with injectable testosterone cypionate. This contrasts sharply with 17-alpha alkylated oral androgens (methyltestosterone, oxymetholone), which are directly hepatotoxic and can cause peliosis hepatis, cholestasis, and hepatocellular carcinoma with sustained use. Injectable esters avoid first-pass hepatic metabolism, so the hepatic adverse-event rate for testosterone cypionate in clinical trials is not statistically separable from placebo. [10] FAERS does contain reports of liver injury attributed to testosterone products, but these likely reflect confounders including concurrent use of oral agents or anabolic-androgenic steroids.

FAERS Data: Post-Market Signal Overview

The FDA Adverse Event Reporting System (FAERS) provides a real-world pharmacovigilance signal, though reports are voluntary and subject to substantial under-reporting and reporting bias.

Volume of Reports

As of the FAERS quarterly data release for Q4 2023, testosterone products as a class had accumulated more than 50,000 primary-suspect adverse event reports since systematic digital filing began. Cardiovascular events (18.3%), endocrine and hormonal disorders (14.7%), and injection-site reactions (6.1%) represent the three largest categories. [8]

Disproportionality Analysis

A 2022 disproportionality analysis of FAERS data published in Drug Safety found a reporting odds ratio (ROR) of 4.2 (95% CI: 3.8 to 4.7) for polycythemia with testosterone products relative to all other drugs in the database, confirming that erythrocytosis remains the most over-represented signal in the post-market dataset. [11] Atrial fibrillation had an ROR of 1.9 (95% CI: 1.6 to 2.3), a finding that preceded and aligned with the TRAVERSE trial result.

Rare and Serious Adverse Events

The table below organizes testosterone cypionate adverse events by estimated incidence tier, drawing on FDA labeling, the T-Trials, TRAVERSE, and FAERS disproportionality data. This framework is not reproduced in any existing competitor article and reflects HealthRX's synthesis of the primary literature.

| Incidence Tier | Adverse Event | Source / Estimated Rate | |---|---|---| | Very common (>10%) | Erythrocytosis (Hct rise) | T-Trials: 22.4% TC vs. 1.7% placebo | | Common (1 to 10%) | Acne / oily skin | T-Trials: 6.4% TC vs. 3.0% placebo | | Common (1 to 10%) | Injection-site pain | FDA label: 1 to 8% | | Common (1 to 10%) | Gynecomastia | FDA pooled data: 5.7% | | Common (1 to 10%) | PSA increase >1.0 ng/mL | T-Trials: ~5% | | Common (1 to 10%) | Atrial fibrillation | TRAVERSE: 3.5% TC vs. 2.4% placebo | | Uncommon (0.1 to 1%) | Testicular atrophy (symptomatic) | Clinical series: varies | | Rare (<0.1%) | Injection-site abscess | Post-market case series | | Rare (<0.1%) | Hepatotoxicity | Case reports only; no RCT signal | | Very rare | Stroke / MI above placebo rate | TRAVERSE: non-inferior to placebo for MACE |

Venous Thromboembolism

The FDA added a warning for venous thromboembolism (VTE) to all testosterone product labels in 2014, following spontaneous reports through FAERS. The absolute rate in controlled trials is low and not statistically separable from placebo in most studies. A 2019 cohort study published in BMJ (N=39,936) found an adjusted hazard ratio of 1.25 (95% CI: 1.01 to 1.55) for VTE in new testosterone users versus non-users in the first six months of therapy. [12] Prescribers should assess baseline VTE risk, including Factor V Leiden and antithrombin III status, before initiating therapy.

Sleep Apnea Exacerbation

Testosterone therapy can worsen or unmask obstructive sleep apnea (OSA) through effects on upper airway muscle tone and hypoxic ventilatory response. The FDA label includes OSA as a warning. In the T-Trials, OSA-related adverse events were numerically higher in the testosterone arm (4.8% vs. 2.7%), though the study was not powered to test this endpoint formally. [3]

Monitoring Protocol to Reduce Adverse Event Rates

Structured monitoring substantially reduces the clinical impact of testosterone cypionate's adverse-event profile. The Endocrine Society 2018 guideline recommends the following minimum schedule: [5]

• Serum testosterone at 3 to 6 months after initiation to confirm levels are in the mid-normal range (400 to 700 ng/dL trough for weekly cypionate dosing).
• Hematocrit at 3 to 6 months and annually thereafter. Dose reduction or phlebotomy if Hct exceeds 54%.
• PSA at 3 to 6 months and then per age-appropriate cancer screening intervals.
• Bone density (DXA) at baseline and every 1 to 2 years in men with osteoporosis risk factors.
• Lipid panel at 12 months, given testosterone's modest lowering effect on HDL cholesterol.

The American Urological Association 2018 guideline on testosterone deficiency adds a recommendation for digital rectal exam at 3 to 6 months in men over 40. [13]